Skip to main content
. 2019 Nov 14;46(12):1205–1216. doi: 10.1111/jcpe.13203
Study reference Formula Year Study initiated Location Measures & inclusion criteria Control Length of measurement N Female Mean age in years (SD)
Nachnani et al., 2019, Summary S2

0.45% SnF2

0.51% SnCl2

0.53% Zn citrate

 2018 California, USA Bleeding sites BS: ≥20 Negative, SMFP 12 weeks 84 69% 38.7 (15.62)
Nachnani, Lee, Gurich, Zou, & Anastasia, 2018, Summary S3

0.45% SnF2

2.5% Zn lactate

 2017 California, USA Bleeding sites LSGI BS: ≥20 Negative, SMFP 4 weeks 49 59% 42.2 (15.26)
Amini, Miner, & Gerlach, 2016, Summary S4

0.45% SnF2

2.5% Zn lactate

 2015 Nevada, USA Bleeding sites BS: n/a Negative, NaF 2 weeks 70 57% 36.1 (11.53)
Amini, Amini, & Gerlach, 2018

0.45% SnF2

2.5% Zn lactate

 2013 Nevada, USA Bleeding sites MGI BS: ≥15 Negative, SMFP 3 weeks 61 57% 33.4 (11.95)
Goyal, Qaqish, He, Anastasia, & Winston, 2017, Summary S5

0.45% SnF2

0.51% SnCl2

0.53% Zn citrate

 2013 Nevada, USA Bleeding sites MGI

BS: ≥5

MGI: 1.75 to 2.3

 Negative, SMFP 12 weeks 100 65% 41.6 (14.12)
Garcia‐Godoy, Duque, Rothrock, Anastasia, & Gerlach, 2015, Summary S6

0.45% SnF2

2.5% Zn lactate

 2012 Florida, USA Bleeding sites LSGI Mild‐to‐moderate gingivitis Negative, SMFP 4 weeks 57 65% 29.1 (8.68)
Gerlach & Amini, 2012

0.45% SnF2

0.46% SnCl2

1.9% Zn lactate

 2009 Nevada, USA Bleeding sites MGI

BS: n/a

MGI: 1.75 to 2.3

 Negative, SMFP 12 weeks 100 60% 33.6 (11.14)
Gerlach, Sagel, Winston, Garcia‐Godoy, & Garcia‐Godoy, 2016, Summary S7

0.45% SnF2

2.5% Zn lactate

 2007 Florida, USA TMQHI Adults with plaque and gingivitis SMFP 11 weeks 91 76% 33.4 (11.19)
Mallatt et al., 2007

0.45% SnF2

2.5% Zn lactate

 2003 Florida, USA Bleeding sites MGI MGI: 1.75 to 2.3 Negative, SMFP 12 weeks 140 62% 37.7 (11.66)
Mankodi et al., 2005

0.45% SnF2

2.5% Zn lactate

 2002 Florida, USA Bleeding sites MGI MGI: 1.75 to 2.3 Negative, SMFP 12 weeks 143 67% 37.2 (10.87)
McClanahan et al., 1997

0.45% SnF2

1.5% SnCl2

1992 Indiana, USA Bleeding sites LSGI BS: >5 Negative, NaF 12 weeks 383 67% 35.9 (11.35)
Beiswanger et al., 1995

0.45% SnF2

1.5% SnCl2

1988 Indiana, USA Bleeding sites LSGI BS: >5 Negative, SMFP 12 weeks 463 69% 33.2 (9.76)